AU2003263393A1 - New heterocyclic amide compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them - Google Patents

New heterocyclic amide compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them

Info

Publication number
AU2003263393A1
AU2003263393A1 AU2003263393A AU2003263393A AU2003263393A1 AU 2003263393 A1 AU2003263393 A1 AU 2003263393A1 AU 2003263393 A AU2003263393 A AU 2003263393A AU 2003263393 A AU2003263393 A AU 2003263393A AU 2003263393 A1 AU2003263393 A1 AU 2003263393A1
Authority
AU
Australia
Prior art keywords
inflammatory
preparation
treatment
pharmaceutical compositions
compositions containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003263393A
Inventor
Prashant Kashinath Bhavar
Neelima Kairatkar Joshi
V.S. Prasada Rao Lingam
Abraham Thomas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glenmark Pharmaceuticals Ltd
Original Assignee
Glenmark Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glenmark Pharmaceuticals Ltd filed Critical Glenmark Pharmaceuticals Ltd
Publication of AU2003263393A1 publication Critical patent/AU2003263393A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C07D207/416—2,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/38—2-Pyrrolones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C07D211/76—Oxygen atoms attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/86—Oxygen atoms
    • C07D211/88—Oxygen atoms attached in positions 2 and 6, e.g. glutarimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
AU2003263393A 2002-09-04 2003-09-03 New heterocyclic amide compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them Abandoned AU2003263393A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN804/MUM/2002 2002-09-04
IN804MU2002 2002-09-04
PCT/IB2003/003721 WO2004022536A1 (en) 2002-09-04 2003-09-03 New heterocyclic amide compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them

Publications (1)

Publication Number Publication Date
AU2003263393A1 true AU2003263393A1 (en) 2004-03-29

Family

ID=31972136

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003263393A Abandoned AU2003263393A1 (en) 2002-09-04 2003-09-03 New heterocyclic amide compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them

Country Status (2)

Country Link
AU (1) AU2003263393A1 (en)
WO (1) WO2004022536A1 (en)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050065624A (en) 2002-10-23 2005-06-29 그렌마크 파머수티칼스 엘티디. Novel tricyclic compounds useful for the treatment of inflammatory and allergic disorders, process for their preparation and pharmaceutical compositions containing them
PT1620429E (en) 2003-04-11 2009-04-28 Glenmark Pharmaceuticals Sa Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
EA009881B1 (en) 2003-06-17 2008-04-28 Пфайзер Инк. N-pyrrolidin-3-yl-amide derivatives as serotonin and noradrenaline re-uptake inhibitors
US7163937B2 (en) 2003-08-21 2007-01-16 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
BRPI0415179A (en) 2003-10-07 2006-11-28 Renovis Inc amide derivatives such as ion channel ligands and pharmaceutical compositions and methods of employing them
BRPI0507971A (en) * 2004-02-23 2007-07-24 Tufts College compound, pharmaceutical composition, use of a compound, method to inhibit the proteolytic activity of a postproline cleavage enzyme and packaged medicine
JPWO2005105743A1 (en) * 2004-04-28 2008-03-13 小野薬品工業株式会社 Nitrogen-containing heterocyclic compound and pharmaceutical use thereof
GB2418425B (en) 2004-08-11 2008-09-03 Univ Cambridge Tech Anti-inflammatory agents
GB2418427A (en) 2004-09-02 2006-03-29 Univ Cambridge Tech Ligands for G-protein coupled receptors
EP1799632A2 (en) 2004-10-13 2007-06-27 Glenmark Pharmaceuticals S.A. Process for the preparation of n-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy-8-methanesulfonamido-dibenzo[b,d]furan-1-carboxamide
BRPI0517211B8 (en) 2004-12-17 2021-05-25 Glenmark Pharmaceuticals Sa compound, pharmaceutical composition and its use.
CN101124229B (en) 2004-12-17 2012-07-18 格兰马克药品股份有限公司 Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders
US7687508B2 (en) 2006-07-28 2010-03-30 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
US7671062B2 (en) 2006-07-28 2010-03-02 Bristol-Myers Squibb Company Modulators of chemokine receptor activity, crystalline forms and process
US7629351B2 (en) 2006-07-28 2009-12-08 Bristol-Myers Squibb Company N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-2-oxo-3-(6-(trifluoromethyl)quinazolin-4-ylamino) pyrrolidin-1-yl)cyclohexyl)acetamide and other modulators of chemokine receptor activity, crystalline forms and process
WO2008083124A1 (en) * 2006-12-28 2008-07-10 Rigel Pharmaceuticals, Inc. N-substituted-heterocycloalkyloxybenzamide compounds and methods of use
CA2678575C (en) * 2007-02-16 2013-10-08 Emisphere Technologies, Inc. Compounds having a cyclic moiety and compositions for delivering active agents
US7662967B2 (en) 2007-08-02 2010-02-16 Cambridge Enterprise Limited Anti-inflammatory compounds and compositions
GB2452696B (en) 2007-08-02 2009-09-23 Cambridge Entpr Ltd 3-(2',2'-dimethylpropanoylamino)-tetrahydropyridin-2-one and its use in pharmaceutical compositions
ES2354550B1 (en) * 2009-06-26 2011-11-15 Institut Univ. De Ciència I Tecnologia, S.A. LIBRARY OF N- (1-PHENYL-2-OXO-3-PIPERIDIL) SULFONAMIDS FOR THE DISCOVERY OF DRUGS.
ES2354551B1 (en) * 2009-07-01 2011-11-15 Institut Univ. De Ciencia I Tecnologia S.A. LIBRARIES OF N- (1-PHENYL-2-OXO-3-PIPERIDIL) SULFONAMIDS FOR THE IDENTIFICATION OF BIOLOGICAL AND PHARMACOLOGICAL ACTIVITY.
US8383812B2 (en) 2009-10-13 2013-02-26 Bristol-Myers Squibb Company N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-A][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, a dual modulator of chemokine receptor activity, crystalline forms and processes
CN102070638A (en) * 2009-11-24 2011-05-25 上海药明康德新药开发有限公司 Preparation method of hexahydro-pyrrolo [3,4-c] pyrrole-1-ketone derivative
TW201309689A (en) 2011-02-07 2013-03-01 Daiichi Sankyo Co Ltd Amino group-containing pyrrolidinone derivatives
CN102690194B (en) * 2011-03-24 2014-06-25 上海通远生物科技有限公司 Preparation method of 3-cyclopropylmethoxy-4-difluoromethoxy-benzoic acid
CN103508883B (en) * 2012-06-17 2015-04-01 重庆圣华曦药业股份有限公司 Method for synthesizing roflumilast intermediate
WO2014024056A1 (en) 2012-08-06 2014-02-13 Daiichi Sankyo Company, Limited Pyrrolidine derivatives with antibacterial properties
CN105579457B (en) 2013-03-20 2017-08-04 拜耳制药股份公司 The substituted acetyl-amino benzamide of N biphenyl 3 and N [3 (acetyl-amino) phenyl] dibenzoyl amine and its it is used as WNT signal pathway inhibitor purposes
EA201500953A1 (en) 2013-03-20 2016-06-30 Байер Фарма Акциенгезельшафт 3-ACETYLAMINO-1- (PENILHETEROARYLAMINOCARBONYL OR PHENILGETEROARILCARBONYLAMINO) BENZENE DERIVATIVES FOR THE TREATMENT OF HYPER-PROLIFERATIVE DISABILITIES
UA121299C2 (en) * 2013-04-12 2020-05-12 Общєство С Огранічєнной Отвєтствєнностью "Фармінтерпрайсез" Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives
CN103351315A (en) * 2013-07-03 2013-10-16 北京化工大学 General preparation method of sulfonyl chloride
EP3140298A1 (en) 2014-05-07 2017-03-15 Pfizer Inc. Tropomyosin-related kinase inhibitors
CA2976971A1 (en) 2015-02-20 2016-08-25 Bayer Pharma Aktiengesellschaft 3-carbamoylphenyl-4-carboxamide and isophtalamide derivatives as inhibitors of the wnt signalling pathway
JP2018507212A (en) 2015-02-20 2018-03-15 バイエル・ファルマ・アクティエンゲゼルシャフト N-phenyl- (morpholin-4-yl or piperazinyl) acetamide derivatives and their use as inhibitors of the WNT signaling pathway
CA2976972A1 (en) 2015-02-20 2016-08-25 Bayer Pharma Aktiengesellschaft 1,3,4-thiadiazol-2-yl-benzamide derivatives as inhibitorsof the wnt signalling pathway
HUE054474T2 (en) 2015-03-30 2021-09-28 Mission Therapeutics Ltd 1-cyano-pyrrolidine compounds as usp30 inhibitors
CN105523954B (en) * 2016-02-05 2017-07-18 徐江平 The alkoxy benzamides class phosphodiesterase 4 inhibitors of 3 the third methoxyl group of ring 4
MX2019012813A (en) 2017-04-26 2020-01-14 Basf Se Substituted succinimide derivatives as pesticides.
WO2018224455A1 (en) 2017-06-07 2018-12-13 Basf Se Substituted cyclopropyl derivatives
WO2018234488A1 (en) 2017-06-23 2018-12-27 Basf Se Substituted cyclopropyl derivatives
CN107915685A (en) * 2017-12-11 2018-04-17 重庆植恩药业有限公司 A kind of preparation method of hydrobromic acid Vortioxetine intermediate
WO2019121143A1 (en) 2017-12-20 2019-06-27 Basf Se Substituted cyclopropyl derivatives
CN108003105B (en) * 2018-01-02 2021-09-07 上海克琴科技有限公司 Method for synthesizing micromolecular amino acid derivative ectoin
US10781172B2 (en) 2018-06-21 2020-09-22 Northwestern University Catalysts and methods for enantioselective conjugate additions of amines to unsaturated electrophiles
EP3613736A1 (en) 2018-08-22 2020-02-26 Basf Se Substituted glutarimide derivatives
AU2019369659A1 (en) 2018-10-29 2021-04-29 Basf Se Process for preparation of optically enriched aldol compounds
CN112969690A (en) 2018-11-06 2021-06-15 巴斯夫欧洲公司 Process for preparing optically enriched isoxazolines
EP3696177A1 (en) 2019-02-12 2020-08-19 Basf Se Heterocyclic compounds for the control of invertebrate pests
CA3206886A1 (en) 2021-02-11 2022-08-18 Nikolas HUWYLER Substituted isoxazoline derivatives
EP4043444A1 (en) 2021-02-11 2022-08-17 Basf Se Substituted isoxazoline derivatives
WO2024033374A1 (en) 2022-08-11 2024-02-15 Syngenta Crop Protection Ag Novel arylcarboxamide or arylthioamide compounds

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1041861A (en) * 1962-03-14 1966-09-07 Organon Labor Ltd Pyrrolidone derivatives and pharmaceutical preparations containing them
NL7016899A (en) * 1969-12-03 1971-06-07
JPS62158253A (en) * 1985-12-28 1987-07-14 Kirin Brewery Co Ltd 4-aminopyridinamide derivative
US5202344A (en) * 1990-12-11 1993-04-13 G. D. Searle & Co. N-substituted lactams useful as cholecystokinin antagonists
IE71647B1 (en) * 1991-01-28 1997-02-26 Rhone Poulenc Rorer Ltd Benzamide derivatives
DK0652868T3 (en) * 1992-07-28 2005-02-14 Aventis Pharma Ltd Inhibitors of c-AMP phosphodiesterase
GB9304920D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
EP0706513B1 (en) * 1993-07-02 2002-05-15 Byk Gulden Lomberg Chemische Fabrik GmbH Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors
GB9315595D0 (en) * 1993-07-28 1993-09-08 Res Inst Medicine Chem New compounds
GB9401460D0 (en) * 1994-01-26 1994-03-23 Rhone Poulenc Rorer Ltd Compositions of matter
PT1064298E (en) * 1998-03-19 2009-01-02 Vertex Pharma Inhibitors of caspases
US6887870B1 (en) * 1999-10-12 2005-05-03 Bristol-Myers Squibb Company Heterocyclic sodium/proton exchange inhibitors and method
AU2001250849A1 (en) * 2000-03-17 2001-10-03 Bristol-Myers Squibb Pharma Company Cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and tnf-alpha
ATE347557T1 (en) * 2000-03-23 2006-12-15 Takeda Pharmaceutical FLUORISOQUINOLINE DERIVATIVES, METHOD FOR THEIR PRODUCTION AND THEIR USE

Also Published As

Publication number Publication date
WO2004022536A1 (en) 2004-03-18

Similar Documents

Publication Publication Date Title
AU2003263393A1 (en) New heterocyclic amide compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
AP2008A (en) Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders; process for their preparation and pharmaceutical compositions containing them
PL376769A1 (en) Novel tricyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
PL374542A1 (en) Benzofused heteroaryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use
IL219396A0 (en) Compounds for the treatment of metabolic disorders and pharmaceutical compositions containing same
IL183827A0 (en) Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders
WO2004046120A3 (en) Diaminotriazoles useful as inhibitors of protein kinases
ZA200610055B (en) Chemical compounds and pharmaceutical compositions containing them for the treatment of inflammatory disorders
IL166108A0 (en) Novel compounds pharmaceutical compositions containing same and methods of use for same
AU2003221745A1 (en) rAAV VECTOR-BASED COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF MAMMALIAN DISEASES
PL374731A1 (en) New compounds, compositions and methods for treatment of inflammatory diseases and conditions
AU2003213787A1 (en) Compositions and methods for the treatment of anorectal disorders
AU2003286741A1 (en) Methods and compositions for diagnosis and therapy of parkin-associated disorders
HUP0200613A2 (en) Compounds and methods for treatment of asthma, allergy and inflammatory disorders, pharmaceutical compositions containing them and their use
AUPS017702A0 (en) Methods and compositions for the treatment of asthma and related disorders
HUP0303751A3 (en) Use of n-phenyl-2-pyrimidineamine derivatives for preparation of pharmaceutical compositions suitable for treating mast cell-based diseases like allergic disorders
IL166054A0 (en) Novel compounds pharmaceutical compositions containing same and methods of use for same
IL163951A (en) Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them
AU2003253130A1 (en) Condensed heterocyclic compounds as pde-iv inhibitors for the treatment of inflammatory and allergic disorders
IL163959A (en) Derivatives of phenyl-sulfonylamino- benzoic acid and pharmaceutical compositions comprising them
IL166097A0 (en) Derivatives of 3-guanidinocarbonyl-1-heteroaryl-pyrrole preparation process and intermediates of this process their use as medicaments and pharmaceutical compositions comprising them
AU2003289652A1 (en) The use of compound helicid for manufacturing medicine to treat depresion and/or disorders caused by depresion
AU2002363228A1 (en) Methods and compositions for the diagnosis and treatment of cellular proliferation disorders using 20750
EP1694242A4 (en) Pharmaceutical formulations of camptothecins and process for making same
AU2003215677A1 (en) N-(morpholin-2yl) methyl acetamide derivatives as ccr-3 antagonists useful in the treatment of inflammatory diseases

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase